Chinese-origin assets are flowing into American pipelines at scale, and the US innovation system converts money and time into approved medicines slower and more expensively than its main competitor. Congress is drafting legislation to restrict Chinese drug licensing. Policymakers are

Princeton, NJ, September 1, 2026 – KYBORA is pleased to announce that it acted as exclusive advisor to Ferring Pharmaceuticals in connection with its strategic partnership with RedHill Biopharma Ltd. (Nasdaq: RDHL) involving Rebyota® and Clenpiq®. Under the agreement, RedHill

This collaboration combines the scientific and commercial expertise of Clarivate’s Life Sciences & Healthcare Consulting practice with KYBORA’s global transaction execution capabilities to accelerate life sciences transactions Princeton, United States, August 13th 2026 – KYBORA, a global investment bank focused

For three decades, biopharma has operated on a simple premise: therapies are expensive because they are hard to make. Scarcity of successful drugs, not demand, has kept prices high. That premise is weakening – from three directions at once. On

KYBORA’s Key Takeaways from BIO International 2026: Navigating Cautious Optimism An Industry at an Inflection Point The Rise of Chinese Biopharma MFN Pricing Reshapes the Ex-US Calculus Capital Is Returning, Driven by the Patent Cliff AI Is Permeating the Value

Most late-stage biopharma deals do not die because of one bad clause. They die because a problem that was visible earlier was never forced into the open. Here’s what that looks like, and why the strategic partner is never one